# OnCo record paper-duo-e-jco-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-duo-e-jco-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-duo-e-jco-2023" ;
  schema:name "DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer"@en ;
  schema:description "Adding durvalumab to first-line chemotherapy delayed progression in advanced endometrial cancer, and adding the PARP inhibitor olaparib to durvalumab maintenance helped further in mismatch repair-proficient tumours."@en ;
  schema:url <https://onco.cc/key-papers/paper-duo-e-jco-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.23.02132>, <https://pubmed.ncbi.nlm.nih.gov/37864337/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.23.02132> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Westin SN, Moore K, Chon HS, et al." ;
  onco:cancers <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/olaparib/> ;
  onco:trials <https://onco.cc/trials/duo-e/> ;
  onco:journals <https://onco.cc/journals/jco/> .